Practical Application and Evaluation of Fortimel in Oncology Patients

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Nov 18, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how a special nutritional drink called Fortimel can help patients with cancer improve their health and quality of life during treatment. The study will include patients with colorectal cancer, certain types of stomach cancer, or advanced lung cancer who are currently receiving therapies like chemotherapy or immunotherapy. To participate, patients need to be able to understand and communicate, have a life expectancy of more than six months, and agree to take part in the study.

Participants in the trial will receive four different flavors of Fortimel over a four-week period, with one flavor provided each week. They will drink 1-2 bottles of this nutritional formula each day, all at no cost. Throughout the study, patients will be supported by a platform that offers nutritional education and guidance. Researchers will check in with participants to see how their nutritional status and overall well-being change during the intervention, with follow-ups continuing for two months after the study ends. This trial is important because it aims to understand how nutrition can play a role in the care of cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients signed informed consent and volunteered to participate in the study
• • Patients diagnosed with colorectal cancer or primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring, undifferentiated adenocarcinoma) or NSCLC stage I-iv. by histopathological examination of primary biopsy
• • Cancer patients who were receiving chemoradiotherapy or immunotherapy were given 2 points for nutritional risk screening, and patients who met the conditions of ONS nutrition intervention were voluntarily enrolled to receive ONS nutrition intervention with Nertronecar
• • Basic reading and communication skills
• • The expected survival time is greater than 6 months
• Exclusion Criteria:
• • Combined cognitive dysfunction, mental disorder, impaired consciousness or unwillingness to partner
• • Contraindications with chemotherapy or immunotherapy
• • Prolonged bed rest, hemiplegia, or coma
• • Intolerance of allergies to nutrients or their main components, such as lactose or galactose
• • In the case of severe gastrointestinal symptoms of liver and kidney dysfunction, the serum creatinine glutamic pyruvic transaminase glutamic oxalacetic transaminase increases by more than 2.5 times, and the fasting blood glucose is over10mmol